Collegium Pharmaceutical (COLL)
(Delayed Data from NSDQ)
$31.10 USD
+0.01 (0.03%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $31.07 -0.03 (-0.10%) 4:22 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
COLL 31.10 +0.01(0.03%)
Will COLL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for COLL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for COLL
Zevra Therapeutics (ZVRA) Reports Next Week: Wall Street Expects Earnings Growth
Collegium Pharmaceutical (COLL) Q2 Earnings Preview: What's in the Cards?
COLL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 33.91% Upside in Collegium Pharmaceutical (COLL): Can the Stock Really Move This High?
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?
Compared to Estimates, Collegium Pharmaceutical (COLL) Q1 Earnings: A Look at Key Metrics
Other News for COLL
Collegium Pharmaceutical Breaks Below 200-Day Moving Average - Notable for COLL
Collegium Pharmaceutical Inc (COLL) Announces Q2 2025 Financial Results Release Date | COLL ...
Collegium Pharmaceutical Breaks Above 200-Day Moving Average - Bullish for COLL
Collegium announces $150M share repurchase program
Collegium Pharmaceutical board authorizes $150M share repurchase program